This dataset describes a randomized clinical trial (Goldman et al., 1996) in which both survival and longitudinal data were collected to compare the efficacy and safety of two antiretroviral drugs, namely ddI (didanosine) and ddC (zalcitabine), in treating HIV-infected patients intolerant or failing zidovudine (AZT) therapy.
data(aids)A data.frame in the unbalanced format with 1405 longitudinal
observations from 467 subjects. The columns are:
idinteger: number for patient identification.
timenumeric: time to death (or censoring).
deathinteger: event indicator. Coded as 0 =
right-censoring, and 1 = death.
obstimenumeric: measurement times for the repeated CD4 count measurements.
CD4numeric: CD4 cell counts measured at obstime.
drugfactor: drug indicator. Coded as ddI = didanosine
and ddC = zalcitabine.
genderfactor: gender indicator. Coded as male and
female.
prevOIfactor: opportunistic infection indicator. Coded as
AIDS = AIDS diagnosis at study entry, and noAIDS = no
previous infection.
AZTfactor: AZT intolerance/failure indicator. Coded as
intolerance or failure.
Goldman A, Carlin B, Crane L, Launer C, Korvick J, Deyton L, Abrams D. Response of CD4 and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996; 11: 161-169 URL: http://www.biostat.umn.edu/~brad/data.html.
heart.valve, epileptic,
mental, liver.